# In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma

## TL;DR

A new copper complex shows strong anti-cancer effects against osteosarcoma in lab and animal tests, outperforming existing treatments.

## Contribution

A tetranuclear Cu(II)-hydrazone complex (Cu4L4) is shown to have superior antitumor activity against osteosarcoma compared to mononuclear analogs and cisplatin.

## Key findings

- Cu4L4 exhibited an IC50 of 0.50 µM against MG-63 cells, significantly lower than cisplatin and its free ligand.
- The complex induced late apoptosis and reduced clonogenic survival in osteosarcoma cells.
- In a xenograft model, Cu4L4 inhibited tumor growth by 43.6% without significant toxicity.

## Abstract

Introduction: Osteosarcoma (OS) is the most common primary malignant bone tumor in children and young adults, with poor prognosis due to relapse, metastasis, and chemoresistance. The search for novel metal-based therapeutics has highlighted copper complexes as promising candidates. Here, we report the in vitro and in vivo antitumor activity of a tetranuclear Cu(II)-hydrazone complex (Cu4L4) derived from (E)-5-chloro-N′-(2-hydroxy-3-methoxybenzylidene)thiophene-2-carbohydrazide. Results: Cytotoxic assays on MG-63 OS cells revealed potent activity with an IC50 of 0.50 ± 0.04 µM, significantly surpassing its free ligand (IC50 = 13.9 ± 1.6 µM) and cisplatin (IC50 = 39.0 ± 1.8 µM). This tetranuclear complex outperforms mononuclear Cu-hydrazones analogs (e.g., 4-fold vs. CuHL1, 2-fold vs. CuHL2, 5-fold vs. CuHL3, 17-fold vs. CuHL4,), and Cu4L4 also exhibits reduced clonogenic survival, induces reactive oxygen species production, and promotes late apoptosis as a main mechanism, being the main mechanism of action involved in anticancer activity. In multicellular tumor spheroids, the complex maintained strong cytotoxicity (IC50 = 4.11 ± 0.12 µM), impaired spheroid integrity, and markedly inhibited cell migration at sub-IC50 concentrations. The tetranuclear architecture confers markedly enhanced antitumor activity relative to the corresponding mononuclear Cu–hydrazone complexes (e.g., 2-fold vs. CuHL1, 4-fold vs. CuHL2, 2-fold vs. CuHL3). In a xenograft model, sustained administration of Cu4L4 (2 mg/kg, i.p., twice weekly) inhibited tumor growth by 43.6%, reduced mitotic index, and increased necrotic area without significant systemic toxicity. Conclusions: Overall, Cu4L4 displayed potent and selective antitumor activity against OS cells in 2D, 3D, and in vivo models, underscoring copper–hydrazone complexes as promising scaffolds for the development of new therapies against OS.